In the face of the high risks of innovative R&D and the escalating costs of commercialisation, partnering has never been more important. Biotech companies, but now increasingly large companies too, are seeking development and market access competencies to share the costs and risks of commercialising a product. Larger companies have recently faced both significant drops in their pipeline productivity and imminent patent expiries for their blockbuster products. Innovation must be found externally to boost internal R&D pipelines, and the many thousands of R&D programmes conducted by small companies provide a good source, if only they were all visible and their value clearly understood. PharmaVentures is ideally positioned to search and evaluate licensing/acquisition targets using its broad and global network of industry executives, and its specific experience in assessing the value of an opportunity.
Our domain expertise in deal making ensures a rapid access and evaluation of product and technology targets and proactively supports the initiation of the transaction